McKesson Corporation (MCK) Earnings Call Transcripts

McKesson Corporation's Latest Earnings Call - Q1 FY2027

In the first quarter of fiscal 2027, McKesson Corporation (MCK:US) reported revenues of $105 billion, an 8% increase year-over-year, and adjusted earnings per share (EPS) of $9.93, up 20%, both exceeding expectations. Management raised full-year adjusted EPS guidance to a range of $44.20 to $45.00, reflecting confidence in continued strong performance across its segments, particularly in North American Pharmaceuticals and Oncology. The results indicate robust operational execution and a positive outlook for the remainder of the fiscal year, despite some market dynamics impacting branded pharmaceutical pricing.

Reported metrics

Guidance from management

Management raised the fiscal 2027 adjusted EPS guidance to $44.20 to $45.00, reflecting confidence in continued strong performance. Revenue growth is anticipated in the range of 5% to 9%.

What management said

And if you reflect specifically on Florida Cancer, we have been very pleased with the work the team has done to integrate them into McKesson. The operations have been very, very solid. Execution has been fantastic. And we are on the high end of the guidance range we provided to you at the time of the acquisition. So it's been very successful, both in the cultural integration, the operational execution and the financi...

Sure. Well, we continue to be pleased with the growth that we're seeing in GLP-1s. There is a vibrant cash market for GLP-1s. It's one of the only product categories out there that I think we could say that's true for. But we've seen very strong growth in the covered segment as well as evidenced by the performance of CoverMyMeds and the revenue that's showing up in APD. There has been some debate about coverage, but ...

What analysts pressed on

Analysts raised concerns about the sustainability of free cash flow, which was negative this quarter, despite improvements from the previous year. There are questions regarding the impact of market dynamics on future revenue growth, particularly in the North American Pharmaceutical segment due to pricing pressures.

Main topics on the call

• Revenue Growth — Revenues increased 8% to $105 billion, driven by higher prescription volumes and strength in oncology and multispecialty segments. Management noted, "3 of our reporting segments delivered double-digit operating profit gr...
• Earnings Performance — Adjusted EPS rose 20% to $9.93, surpassing expectations. This growth was attributed to strong operational performance and a lower share count due to share repurchases, as stated by Kenny Cheung, "Adjusted earnings per sh...
• Guidance Increase — Management raised the full-year adjusted EPS guidance to $44.20 to $45.00 from the previous range of $43.80 to $44.60, indicating confidence in sustained performance. Kenny Cheung remarked, "We are pleased with the conti...
• Oncology and Multispecialty Growth — This segment saw a remarkable 33% revenue increase, driven by existing provider solutions and new business wins. Excluding contributions from the Core Ventures acquisition, organic growth was approximately 24%, showcasin...

Read the full McKesson Corporation transcript (Q1 FY2027) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 66 McKesson Corporation earnings call transcripts on record, spanning January 14, 2020 to August 5, 2026. Based on this history, McKesson Corporation reports quarterly. The most recent call on file is dated August 5, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

MCK

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Providers and Services

Calls on record

66

First call

January 14, 2020

Most recent

August 5, 2026

Reporting cadence

quarterly